Published January 1, 2017
| Version v1
Journal article
Open
GLP-1 nanomedicine alleviates gut inflammation
Creators
- 1. Univ Illinois, Coll Med, Div Gastroenterol & Hepatol, Dept Med, Chicago, IL USA
- 2. Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL USA
Description
The gut hormone, glucagon like peptide-1 (GLP-1) exerts anti-inflammatory effects. However, its clinical use is limited by its short half-life. Previously, we have shown that GLP-1 as a nanomedicine (GLP-1 in sterically stabilized phospholipid micelles, GLP-1-SSM) has increased in vivo stability. The current study was aimed at testing the efficacy of this GLP-1 nanomedicine in alleviating colonic inflammation and associated diarrhea in dextran sodium sulfate (DSS) induced mouse colitis model. Our results show that GLP-1-SSM treatment markedly alleviated the colitis phenotype by reducing the expression of pro-inflammatory cytokine IL-1 beta, increasing goblet cells and preserving intestinal epithelial architecture in colitis model. Further, GLP-1-SSM alleviated diarrhea (as assessed by luminal fluid) by increasing protein expression of intestinal chloride transporter DRA (down regulated in adenoma). Our results indicate thatGLP-1 nanomedicine may act as a novel therapeutic tool in alleviating gut inflammation and associated diarrhea in inflammatory bowel disease (IBD). Published by Elsevier Inc.
Files
bib-30aa7d0d-71d9-48ef-a6e6-c91c8a64526c.txt
Files
(272 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:cd5e165661d326a93d4cfdb95cb4e36a
|
272 Bytes | Preview Download |